CAS 89663-86-5
:Lipoxin A4
Description:
Lipoxin A4 (LXA4) is a biologically active lipid mediator that plays a crucial role in the resolution of inflammation. It is derived from arachidonic acid through the lipoxygenase pathway and is characterized by its unique structure, which includes a trihydroxy fatty acid backbone. LXA4 is known for its anti-inflammatory properties, promoting the cessation of neutrophil recruitment and facilitating the clearance of apoptotic cells. This compound interacts with specific receptors, such as ALX/FPR2, to exert its effects on various immune cells. In addition to its role in inflammation resolution, Lipoxin A4 has been implicated in various physiological processes, including tissue repair and modulation of immune responses. Its synthesis can be influenced by various stimuli, including cytokines and other inflammatory mediators. Due to its significant biological functions, LXA4 is of interest in therapeutic research, particularly in conditions characterized by chronic inflammation, such as asthma and cardiovascular diseases. Overall, Lipoxin A4 exemplifies the complex interplay between lipid mediators and the immune system.
Formula:C20H32O5
InChI:InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1
InChI key:InChIKey=IXAQOQZEOGMIQS-SSQFXEBMSA-N
SMILES:[C@H]([C@H](CCCC(O)=O)O)(/C=C/C=C/C=C\C=C\[C@H](CCCCC)O)O
Synonyms:- (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-Trihydroxy-7,9,11,13-eicosatetraenoic acid
- (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
- 5S,6R,15S-Trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid
- 7,9,11,13-Eicosatetraenoic acid, 5,6,15-trihydroxy-, (5S,6R,7E,9E,11Z,13E,15S)-
- 7,9,11,13-Eicosatetraenoic acid, 5,6,15-trihydroxy-, [5S-(5R*,6S*,7E,9E,11Z,13E,15R*)]-
- LXA<sub>4</sub>
- Lipoxin A
- Lipoxin A<sub>4</sub>
- LXA
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Lipoxin A4
CAS:<p>Lipoxin A4 (LXA4) is an endogenous lipoxygenase-derived arachidonic acid-like mediator with anti-inflammatory properties.</p>Formula:C20H32O5Purity:95%Color and Shape:SolidMolecular weight:352.47Lipoxin A4
CAS:<p>Lipoxin A4 is an inhibitor that has been shown to have potent anticancer activity. It has been found to inhibit the growth of tumor cells in Chinese hamster ovary cells and human cancer cell lines. Lipoxin A4 is a protein kinase inhibitor that targets several kinases, including Akt, ERK1/2, and p38 MAPK. This drug has also been found to induce apoptosis in cancer cells by activating caspase-3 and other apoptotic pathways. In addition to its anticancer properties, Lipoxin A4 has also been investigated as an anti-inflammatory agent and has shown promising results in animal models of inflammation. Lipoxin A4 analogs have been developed for use as potential therapeutic agents, including dabigatran, a direct thrombin inhibitor used for the prevention of stroke and systemic embolism in patients with atrial fibrillation.</p>Formula:C20H32O5Purity:Min. 95%Molecular weight:352.5 g/mol




